´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 22nd KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2024-03-23
±³À°ÀÏÀÚ : 2024-03-23
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : The 22nd KUOS Multidisciplinary Conference(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574
À̸ÞÀÏ : app@app2010.com
±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í Àü¹®ÀÇ: 30,000¿ø / Àü°øÀÇ, ±ºÀÇ°ü, °£È£»ç: 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:20 MRI and renal tumors À̽¼ö(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:20~09:40 Contrast-enhanced US and renal tumors ±è»óÀ±(¼¿ïÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:40~10:00 (±¸¿¬) 1. Optimal treatment strategy for patients with oligometastatic RCC ±Ç¹Î¼®(¾ÆÁÖÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:00~10:20 (±¸¿¬) 2. Role of adjuvant pembrolizumab after metastatectomy in oligometastatic RCC: based on updated results of KN564 trial ¼Û丰(¿ï»êÀÇ´ë ºñ´¢ÀÇÇаú)
ÈÞ½Ä 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:20~10:40 Break ( )
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:40~11:10 Prostate Cancer Genome Profiling – The Need for Global Inclusion Vanessa Hayes(University of Sydney)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:10~11:23 (±¸¿¬) 1. Neoadjuvant treatment for advanced prostate cancer ¹Ú¼º¿ì(ºÎ»êÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:23~11:36 (±¸¿¬) 2. Genetic testing for advanced prostate cancer ¿ÀÁÖÇö(°¡Å縯ÀÇ´ë ÇÙÀÇÇаú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:36~11:50 (±¸¿¬) 3. PSMA targeted therapy for mCRPC ÀÓÀ缺(Ãæ³²ÀÇ´ë ºñ´¢ÀÇÇаú)
±âŸ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:50~12:00 Photo ( )
½Ä»ç 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:00~13:40 Lunch ( )
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:40~14:10 Antibody-Drug Conjugates (ADC) °³¹ßÀÇ ÇöÀç¿Í ¹Ì·¡ Á¤Ã¶¿õ(·¹°íÄ·¹ÙÀÌ¿À ADC ¿¬±¸¼ÒÀå)
ÈÞ½Ä 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:10~14:30 Break ( )
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:30~14:50 Urothelial carcinoma: 2022 5th WHO classification ¹®°æö(¼¿ïÀÇ´ë º´¸®°ú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:50~15:10 What¡¯s new about kidney tumors? ±è¿µ¾Æ(¼¿ïÀÇ´ë º´¸®°ú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:20 (±¸¿¬) 1. What is the optimal regimen and schedule for NAC in MIBC ±èÀÎÈ£(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:20~15:30 (±¸¿¬) 2. Is post NAC clinical assessment truly necessary, and if so, how should it be conducted ¹Ú½Âö(¿ø±¤ÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:30~15:40 (±¸¿¬) 3. Should radical cystectomy be performned for MIBC patients who achieve a cT0 Status after NAC ¼ºÇöȯ(¼º±Õ°üÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:40~15:50 (±¸¿¬) 4. What is the evidence supporting NAC for bladder preservation in MIBC ÀÌ»ó¿í(¼øõÇâÀÇ´ë ºñ´¢ÀÇÇаú)